EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reactive Cutaneous Capillary Endothelial Proliferation in Esophageal Squamous Cell Carcinoma Patients Treated With Camrelizumab‐Based Therapy: A Pooled Analysis of Two Phase 3 Trials

Jia Liu, Ye He, Mingming He, Fan Chen, Zhiguo Hou, Zhaoqing Zheng, Chaoyu Lin, Aichun Chen, Ruihua Xu, Huiyan Luo, ESCORT‐1st Study Group, ESCORT Study Group

MedComm · 2026-08 · 7 (8)

DOI: 10.1002/mco2.70917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm, online erschienen am 09.08.2026. Verfasst von Jia Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology Sun Yat-sen University Cancer Center Guangzhou China. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common immune‐related adverse event associated with camrelizumab and has been linked to favorable outcomes. We conducted a pooled analysis of two phase III randomized trials, ESCORT (NCT03099382) and ESCORT‐1st (NCT03691090), to evaluate the clinical characteristics and prognostic relevance of RCCEP in patients with advanced esophageal squamous cell carcinoma (ESCC) receiving camrelizumab‐based therapy. A total of 526 patients treated with camrelizumab, either alone or in combination with chemotherapy, were included. Objective response rate (ORR), progression‐free survival (PFS), and overall survival (OS) were compared according to RCCEP status. Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline imbalances, and a 2‐month landmark analysis was performed to reduce lead‐time bias. Overall, 420 patients (79.8%) developed RCCEP, mostly grade 1–2 (99.0%), with no RCCEP‐related treatment discontinuations. The median onset was 1.18 months, and the duration was 3.12 months. RCCEP‐positive patients showed a higher ORR (52.4% vs. 26.4%), longer PFS (5.55 vs. 1.94 months; HR = 0.45), and OS (13.40 vs. 6.11 months; HR = 0.47), consistent after landmark analysis. These findings suggested that RCCEP was frequent yet manageable and may serve as a potential on‐treatment biomarker of camrelizumab benefit in ESCC.

Schlagwörter

Stichwörter der Autor:innen

camrelizumabesophageal squamous cell carcinomareactive cutaneous capillary endothelial proliferation

Autor:innen und Institutionen

  • Department of Medical Oncology Sun Yat-sen University Cancer Center Guangzhou China.
  • Department of Medical Affairs Jiangsu Hengrui Pharmaceuticals Co., Ltd. Jiangsu China.

Zitieren

APA

Liu, J., He, Y., He, M., Chen, F., Hou, Z., Zheng, Z., Lin, C., Chen, A., Xu, R., Luo, H., & ESCORT‐1st Study Group, ESCORT Study Group (2026). Reactive Cutaneous Capillary Endothelial Proliferation in Esophageal Squamous Cell Carcinoma Patients Treated With Camrelizumab‐Based Therapy: A Pooled Analysis of Two Phase 3 Trials. MedComm, 7(8). https://doi.org/10.1002/mco2.70917

Vancouver

Liu J, He Y, He M, Chen F, Hou Z, Zheng Z, et al. Reactive Cutaneous Capillary Endothelial Proliferation in Esophageal Squamous Cell Carcinoma Patients Treated With Camrelizumab‐Based Therapy: A Pooled Analysis of Two Phase 3 Trials. MedComm. 2026;7(8). doi:10.1002/mco2.70917

BibTeX
@article{Liu2026,
  author = {Liu, Jia and He, Ye and He, Mingming and Chen, Fan and Hou, Zhiguo and Zheng, Zhaoqing and Lin, Chaoyu and Chen, Aichun and Xu, Ruihua and Luo, Huiyan and ESCORT‐1st Study Group, ESCORT Study Group, ESCORT‐1st Study Group, ESCORT Study Group},
  title = {Reactive Cutaneous Capillary Endothelial Proliferation in Esophageal Squamous Cell Carcinoma Patients Treated With Camrelizumab‐Based Therapy: A Pooled Analysis of Two Phase 3 Trials},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {8},
  doi = {10.1002/mco2.70917}
}
Kostenlos starten →